Indication

For the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.

Medicine details

Medicine name:
burosumab (Crysvita)
SMC ID:
SMC2240
Pharmaceutical company
Kyowa Kirin
BNF chapter
Endocrine system
Submission type
Ultra-orphan initial assessment
Status
Publication due date:
10 February 2020
SMC meeting date:
07 January 2020
Patient group submission deadline:
02 December 2019